LAVA Therapeutics N.V.
US ˙ NasdaqGS ˙ NL0015000AG6

SecurityLVTX / LAVA Therapeutics N.V.
InsiderVersant Venture Capital VI, L.P.
This page shows the track record and history of Versant Venture Capital VI, L.P. insider trades in LAVA Therapeutics N.V.. The SEC defines Insiders as officers, directors, or significant investors (greater than 10% ownership) in a company. It is illegal for insiders to make trades in their companies based on material, non-public information ("MNPI"). This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4.
Insider Purchases - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made by Versant Venture Capital VI, L.P. in LVTX / LAVA Therapeutics N.V.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

LVTX / LAVA Therapeutics N.V. Insider Trades
Insider Sales - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made by Versant Venture Capital VI, L.P. in LVTX / LAVA Therapeutics N.V.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
2025-09-18 366,111 1.4418 366,111 1.4418 527,859 0 1.4700 10,325 1.96
2025-09-18 228,791 1.4418 228,791 1.4418 329,871
2025-09-17 362,806 1.4892 362,806 1.4892 540,291
2025-09-17 226,726 1.4892 226,726 1.4892 337,640
2025-09-16 307,707 1.5332 307,707 1.5332 471,776
2025-09-16 192,293 1.5332 192,293 1.5332 294,824

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

LVTX / LAVA Therapeutics N.V. Insider Trades
Insider Transaction History
File
Date
Trade
Date
Form Insider Ticker Security Title Code 10b5-1 Direct Exercise
Price
Unit
Price
Units
Changed
Value
Changed (1K)
Remaining
Options
Remaining
Shares
2025-09-18 2025-09-18 4 Versant Venture Capital VI, L.P. LVTX Common Stock S - Sale I 1.4418 -228,791 -330 532,870
2025-09-18 2025-09-18 4 Versant Venture Capital VI, L.P. LVTX Common Stock S - Sale D 1.4418 -366,111 -528 2,370,533
2025-09-18 2025-09-17 4 Versant Venture Capital VI, L.P. LVTX Common Stock S - Sale I 1.4892 -226,726 -338 761,661
2025-09-18 2025-09-17 4 Versant Venture Capital VI, L.P. LVTX Common Stock S - Sale D 1.4892 -362,806 -540 2,736,644
2025-09-18 2025-09-16 4 Versant Venture Capital VI, L.P. LVTX Common Stock S - Sale I 1.5332 -192,293 -295 988,387
2025-09-18 2025-09-16 4 Versant Venture Capital VI, L.P. LVTX Common Stock S - Sale D 1.5332 -307,707 -472 3,099,450
2025-02-06 3 Versant Venture Capital VI, L.P. LVTX Common Shares D 3,407,157
2025-02-06 3 Versant Venture Capital VI, L.P. LVTX Common Shares I 1,180,680
P
Åbent marked eller privat køb af ikke-afledte eller afledte værdipapirer
S
Åbent marked eller privat salg af ikke-afledte eller afledte værdipapirer
A
Tildeling, tildeling eller anden erhvervelse af værdipapirer fra virksomheden (såsom en option)
C
Konvertering af derivat
D
Salg eller overførsel af værdipapirer tilbage til virksomheden
F
Betaling af udnyttelseskurs eller skatteforpligtelse ved brug af en del af værdipapirer modtaget fra selskabet
G
Gave af værdipapirer af eller til insideren
K
Aktieswaps og lignende sikringstransaktioner
M
Udnyttelse eller konvertering af afledt værdipapir modtaget fra virksomheden (såsom en option)
V
En transaktion rapporteret frivilligt på formular 4
J
Andet (ledsaget af en fodnote, der beskriver transaktionen)